|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Marijuana, a psychoactive drug that activates cannabinoid-1 (CB1) receptors in the brain, is the most prevalently abused illicit drug among American adolescents and young adults.
|
31120283 |
2019 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CNR1 variation emerged as a moderator of the relationship between trait impulsivity and marijuana problems, thus suggesting that marijuana users with CNR1 risk variants and a higher trait impulsivity are at greater risk for developing marijuana-related problems and supporting a role for CNR1 in a broader impulsivity phenotype.
|
24172113 |
2013 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cannabinoid receptor 1 (CNR1) gene polymorphisms have been associated with central and peripheral effects of cannabis and schizophrenia pathophysiology.
|
26071625 |
2015 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CNR1 haplotypes were formed from four CNR1 SNPs (rs806368, rs1049353, rs2023239, and rs6454674) and tested with level of cannabis exposure to assess their interactive effects on the lingual gyrus, cingulum (right and left) and rolandic operculum, regions showing cannabis exposure effects in the SPM8 analyses.
|
27500453 |
2016 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A single nucleotide polymorphism in the cannabis receptor-1 gene (CNR1), rs2023239, has been associated with CD diagnosis and intermediate phenotypes, including abstinence-induced withdrawal, cue-elicited craving, and parahippocampal activation to cannabis cues.
|
22669173 |
2012 |
|
Marijuana Abuse
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because the psychotropic effects and abuse liability of cannabis prevent its therapeutic application in depression and anxiety states, we decided to investigate the effects of the combination of ineffective doses of cannabinoid CB1 receptor agonist arachidonylcyclopropylamide (ACPA) and β-carbolines on anxiety- and depression-related behaviors in male NMRI mice.
|
30797851 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cannabinoids and their principle psychoactive target, the cannabinoid type 1 receptor (CB1R), impact a number of alcohol-related properties, and although alcohol and cannabis are often co-used, particularly in adolescence, few animal models of this phenomenon exist.
|
31524960 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cannabinoids are the active ingredients of marijuana, which interact with cannabinoid receptors such as CNR1 and CNR2 to activate cellular signaling pathways.
|
29884300 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Choline transported into the amniotic fluid from the mother activates α7-nicotinic acetylcholine receptors on fetal cerebro-cortical inhibitory neurons, whose development is impeded by cannabis blockade of their cannabinoid-1(CB1) receptors.
|
31364525 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Consumption of cannabinoid receptor-1 (CB-1) agonist such as cannabis is widely taken in 3,4- methylenedioxymethamphetamine (MDMA) or ecstasy users; it has been hypothesized that co-consumption of CB-1 agonist might protect neurons against MDMA toxicity.
|
28167133 |
2017 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of CNR1 tSNPs and marijuana abuse/dependence on brain volumes and neurocognition were assessed using ANCOVA, including co-morbid alcohol/non-marijuana illicit drug misuse as covariates.
|
21420833 |
2011 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
CTD_human |
Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence.
|
19016476 |
2009 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, DLPFC activity in the cluster associated with the CNR1 by PTGS2 interaction was negatively correlated with behavioral efficiency and positively correlated with frequency of cannabis use in cannabis users.
|
27261878 |
2016 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, it is unclear which constituent in cannabis is responsible for these effects, or whether these are cannabinoid receptor 1 (CB1R) mediated.
|
29604295 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast, delta-9-tetrahydrocannabinol (THC), the primary psychoactive component in cannabis, is associated with acute and neurodevelopmental propsychotic side effects through its interaction with central cannabinoid type 1 receptors (CB1Rs).
|
29063964 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we assessed the influence of another cannabinoid-related gene, mitogen-activated protein kinase 14 (MAPK14), and potential MAPK14-CNR1 gene-gene interactions in conferring brain volume abnormalities among schizophrenia patients with marijuana abuse/dependence.
|
22850347 |
2013 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vitro studies suggest that synthetic cannabinoids in these preparations are potent agonists at central cannabinoid CB1 receptors (CB1Rs), but few investigations have delineated their cellular effects, particularly in comparison with the psychoactive component of marijuana, Δ<sup>9</sup> -tetrahydrocannabinol (Δ<sup>9</sup> -THC).
|
26732435 |
2017 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant.
|
30077950 |
2018 |
|
Marijuana Abuse
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Since marijuana intoxication has a potent blocking effect on short-term memory we examined the association between the CNR1 alleles and the P300 wave amplitude at three electrodes in 35 alcohol and drug addicts, by MANOVA.
|
9106243 |
1997 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synthetic cannabinoids are, typically, full agonists at the cannabinoid CB1 receptor, and therefore considerably more potent than natural cannabis and may have correspondingly more serious psychological effects.
|
30789300 |
2019 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken collectively, the atypical pharmacodynamic properties of AB-PINACA at CB1Rs relative to Δ<sup>9</sup>-THC (e.g., higher potency/efficacy and greater production of desensitization), coupled with an unusual metabolic profile (e.g., production of metabolically stable active phase I metabolites) may contribute to the pronounced adverse effects observed with abuse of this SCB compared to marijuana.
|
30319418 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
The central cannabinoid receptor (CB1) mediates the pharmacological activities of cannabis, the endogenous agonist anandamide and several synthetic agonists.
|
10441206 |
1999 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
The cannabinoid receptor 1 (CB<sub>1</sub>) is the principal target of the psychoactive constituent of marijuana, the partial agonist Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC).
|
28678776 |
2017 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
The cannabinoid-1 receptor (CB1R) agonist Δ9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, adversely effects working memory performance in humans.
|
28641496 |
2018 |
|
Marijuana Abuse
|
0.400 |
Biomarker
|
disease |
BEFREE |
The CB1/Cnr1 receptor is the major brain site at which cannabinoid marijuana constituents are psychoactive as well as the principal brain receptor for endogenous anandamide ligands.
|
15289816 |
2004 |